基本信息
views: 7
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Lisa A. Carey, MD, ScM, FASCO, is an experienced clinical/translational trialist, UNC Lineberger Comprehensive Cancer Center Deputy Director for Clinical Science and co-Leader of the Breast Program, and co-Chair of the Breast Committee of the Alliance national cooperative group.
Lisa Carey’s research interests focus upon breast cancer, including examination of different subtypes of breast cancer, evaluation of new chemotherapy agents in early and metastatic breast cancer, and examination of tumor characteristics that predict response to therapy.
She has worked extensively with scientists across UNC Lineberger and the UNC Gillings Global School of Public Health to better understand and characterize the molecular subtypes of breast cancer so that we may develop better prevention and treatment strategies. With Drs. Perou and Millikan, she identified the elevated risk of the poor-prognosis basal-like breast cancer subtype in young African-American women. She is a world-wide expert in triple negative breast cancer, and led the first trial looking at a new drug regimen in this breast cancer subtype.
Her research spans the spectrum from early curative breast cancer to metastatic disease. She has worked extensively developing trials that use neoadjuvant, or preoperative, chemotherapy for breast cancer in order to address both clinical questions about the best regimens, as well as scientific questions regarding sensitivity or resistance to drugs. She led a large NCI-sponsored trial in HER2-positive breast cancer that examined dual HER2-targeting with two anti-HER2 drugs that found that while drug regimen was important in outcome, even more important were tumor characteristics such as subtype and evidence of immune cell activation. Based on this work, she has put together an international team looking at the molecular markers responsible this variation in response and survival, and her efforts as co-chair of the national cooperative group, Alliance, have resulted in two NCI trials examining these markers and optimizing treatment. In addition, she is actively involved in examining novel agents in metastatic breast cancer. Her Tumor Donation Program has contributed novel information regarding the genetic differences between the original primary breast cancer and the metastases in distant organs, and her HARMONY trial is examining how more biologic information might inform clinical decision-making in metastatic breast cancer. This work in part spawned the AURORA-US multicenter initiative furthering this examination of the molecular landscape of metastatic disease; she serves on the Steering Committee for that effort.
She serves in national leadership roles, including as a member of the National Cancer Institute Breast Cancer Steering Committee, Co-Chair of the NCI-sponsored Alliance Breast Committee, Co-Chair of the Translational Breast Cancer Research Consortium Steering Committee, and member of the Board of Directors of the American Society of Clinical Oncology.
Lisa Carey’s research interests focus upon breast cancer, including examination of different subtypes of breast cancer, evaluation of new chemotherapy agents in early and metastatic breast cancer, and examination of tumor characteristics that predict response to therapy.
She has worked extensively with scientists across UNC Lineberger and the UNC Gillings Global School of Public Health to better understand and characterize the molecular subtypes of breast cancer so that we may develop better prevention and treatment strategies. With Drs. Perou and Millikan, she identified the elevated risk of the poor-prognosis basal-like breast cancer subtype in young African-American women. She is a world-wide expert in triple negative breast cancer, and led the first trial looking at a new drug regimen in this breast cancer subtype.
Her research spans the spectrum from early curative breast cancer to metastatic disease. She has worked extensively developing trials that use neoadjuvant, or preoperative, chemotherapy for breast cancer in order to address both clinical questions about the best regimens, as well as scientific questions regarding sensitivity or resistance to drugs. She led a large NCI-sponsored trial in HER2-positive breast cancer that examined dual HER2-targeting with two anti-HER2 drugs that found that while drug regimen was important in outcome, even more important were tumor characteristics such as subtype and evidence of immune cell activation. Based on this work, she has put together an international team looking at the molecular markers responsible this variation in response and survival, and her efforts as co-chair of the national cooperative group, Alliance, have resulted in two NCI trials examining these markers and optimizing treatment. In addition, she is actively involved in examining novel agents in metastatic breast cancer. Her Tumor Donation Program has contributed novel information regarding the genetic differences between the original primary breast cancer and the metastases in distant organs, and her HARMONY trial is examining how more biologic information might inform clinical decision-making in metastatic breast cancer. This work in part spawned the AURORA-US multicenter initiative furthering this examination of the molecular landscape of metastatic disease; she serves on the Steering Committee for that effort.
She serves in national leadership roles, including as a member of the National Cancer Institute Breast Cancer Steering Committee, Co-Chair of the NCI-sponsored Alliance Breast Committee, Co-Chair of the Translational Breast Cancer Research Consortium Steering Committee, and member of the Board of Directors of the American Society of Clinical Oncology.
Research Interests
Papers共 710 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
JAMA oncologyno. 5 (2024): 603-611
Cancer Researchno. 9_Supplement (2024): PO3-05
Cancer Researchno. 9_Supplement (2024): PO4-01
Cancer epidemiology, biomarkers & preventionpp.OF1-OF8, (2024)
Cancer Researchno. 9_Supplement (2024): PO1-15
L. García Estevez,A. Bardia,H.S. Rugo,L.A. Carey,V.C. Dieras,S. Loibl, M. Piccart,L. Gianni,K. Kalinsky,J. O'Shaughnessy,S.A. Hurvitz, E. Harting,
ESMO Open (2024)
Journal of geriatric oncologyno. 6 (2024): 101813-101813
Cancer Researchno. 9_Supplement (2024): PO4-19
Clinical cancer research : an official journal of the American Association for Cancer Researchno. 4 (2024): 793-802
JAMA oncologyno. 3 (2024): 362-371
Load More
Author Statistics
#Papers: 708
#Citation: 45073
H-Index: 88
G-Index: 206
Sociability: 9
Diversity: 0
Activity: 9
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn